A new study has found that the diabetes drug tirzepatide helps people lower their blood sugar and lose weight more quickly ...

QWINT-3 evaluated the efficacy and safety of once-weekly efsitora compared to once-daily insulin degludec for 78 weeks in adults with type 2 diabetes currently treated with basal insulin.

The results of the ONWARDS 2 trial of insulin icodec showed that it was as effective as daily dosing with Novo Nordisk's Tresiba (insulin degludec) once per day at controlling blood glucose, as ...

Pharmac is seeking public feedback on a proposal to fund a new, additional type of insulin for people with diabetes from 1 May 2025. The new medicine (branded as Ryzodeg) is a combination of two other ...

The approval covers all 27 European Union member states. Tresiba (insulin degludec) is a once-daily new-generation based insulin analogue with an ultra-long duration of action. Ryzodeg (insulin ...

Ryzodeg ® 70/30 contains two types of insulin: Basal insulin called insulin degludec - this has a long blood sugar level lowering effect. Rapid-acting insulin called insulin aspart - this lowers ...

Ryzodeg ® 70/30 contains two types of insulin: Basal insulin called insulin degludec - this has a long blood sugar lowering effect. Rapid acting insulin called insulin aspart - this lowers your ...

Eli Lilly has released detailed results from the Phase III QWINT-2 and QWINT-5 trial showing that its once weekly insulin efsitora (efsitora alfa) demonstrated a similar reduction in HbA1C levels ...

including long-acting insulin degludec, rapid-acting insulin aspart, and premix insulin preparations including the combination of insulin degludec and aspart. To improve the convenience of our ...

The last few years have been tough for the insulin market, with recent policies and high-level pressure forcing companies to ...